Clinical trial · Observational
Application Value of CTCs Detection for Advanced Gastric Cancer Patients
A Single Center Observational Study to Evaluate the Application Value of Circulating Tumor Cell Detection for Advanced Gastric Cancer Patients in Prediction of the Prognosis and Evaluation of the Outcome of Adjuvant Chemotherapy
NCT03156777CI-TRIAL-00027617unknownClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Evaluating the application value of a new circulating tumor cell detection method for advanced gastric cancer patients in prediction of the prognosis and early evaluation of the result of postoperation adjuvant chemotherapy.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Circulating Tumor Cells | — | UNRESOLVED | — |
| Gastric Cancer | Malignant Gastric Neoplasm | CURATED_BROADER | 0.80 |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- Number of circulating tumor cell (CTC)
- timeFrame
- Up to 2 years from start of study
- description
- Number of the circulating tumor cell in peripheral blood from advanced gastric cancer patients undergoing D2 radical resection followed by first-line chemotherapy
Secondary outcomes (3)
- measure
- Profile and Portion of circulating tumor cell (CTC)
- timeFrame
- Up to 2 years from start of study
- description
- Profile and Portion of the circulating tumor cell in peripheral blood from advanced gastric cancer patients undergoing D2 radical resection followed by first-line chemotherapy. There are three type of CTCs: epithelial type CTC，mesenchymal type CTC and mixed type CTC. The portion of different type of CTC were calculated, for example: the portion of epithelia type CTC number to total CTCs,etc.
- measure
- Progression-free survival
- timeFrame
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 75 Years
Show eligibility criteria text
Inclusion Criteria: Subjects eligible for enrollment must meet all of the following criteria: 1. Provide signed informed consent. The subject is capable of understanding and complying with parameters as outlined in the protocol and able to sign informed consent, approved by the Independent Ethic Committee (IEC)/Institutional Review Board (IRB) prior to the initiation of any study-specific procedures 2. Men or women aged \>= 18 years and \<=75 years. 3. Eastern Cooperative Oncology Group Performance Status (ECOG) \<= 2. 4. Histologically confirmed adenocarcinoma of the stomach, gastroesophageal junction. 5. Metastatic disease or locally advanced disease not amenable to curative surgery. 6. Radiographically assessable, non-measurable disease or measurable disease as per RECIST criteria. 7. Life expectancy of at least 12 weeks with tumor and at least 5 years without tumor from the time of enrollment. 8. No other malignancy within the past 5 years except adequately treated basal cell or squamous cell skin cancer or carcinoma in situ of the cervix. 9. No prior chemotherapy for advanced disease. - Exclusion Criteria: Subjects meeting any of the following criteria must not be enrolled in the study: 1. Gastric carcinoid, sarcomas, or squamous cell cancer. 2. Pregnant or lactating females. 3. Significant neurological or psychiatric disorders (psychotic disorders, dementia or seizures) that would prohibit the understanding and giving of informed consent. 4. Active Hepatitis B or C or history of an HIV infection. 5. Active uncontrolled infection. -
References
Publications (0)
Data not yet available
No reference posted for this study.